Chapter 13 Thrombolytic Therapies

Blue Books of Practical Neurology

Volumn 29, Issue C, 2004, Pages 267-281

  Al Senani, Fahmi M ^a   Grotta, James C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957244797     PISSN: 18773419     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-3419(09)70088-1     Document Type: Article

References (38)

1. Sussman B.J., and Fitch T.S. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 167 (1958) 1705-1709
2. The National Institute of Neurological Disorders and Stroke (NINDS). rt-PA Stroke Study Group: tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
3. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025
4. Hacke W., Kaste M., Fieschi C., et al. Randomised double-blind placebo-controlled trial of throm-bolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 352 (1998) 1245-1251
5. Clark W.M., Wissman S., Albers G., et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 282 (1999) 2019-2026
6. The Multicenter Acute Stroke Trial-Europe Study Group (MAST-E). Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 335 (1996) 145-150
7. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346 (1995) 1509-1514
8. Donnan G.A., Davis S.M., Chambers B.R., et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 276 (1996) 961-966
9. Marler J.R., Tilley B.C., Lu M., et al. Early stroke treatment associated with better outcome: The NINDS rt-PA Stroke Study. Neurology 55 (2000) 1649-1655
10. The NINDS rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 28 (1997) 2109-2118
11. Brott T.G., Haley E.C., Levy D.E., et al. Urgent therapy for stroke part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23 (1992) 632-640
12. Haley E.C., Levy D.E., Brott T.G., et al. Urgent therapy for stroke part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 23 (1992) 641-645
13. Tanne D., Bates V.E., Verro P., et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 53 (1999) 424-427
14. Buchan A.M., Barbar P.A., Newcommon N., et al. Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology 54 (2000) 679-684
15. Patel S.C., Levine Sr., Tilley B.C., et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 286 (2001) 2830-2838
16. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Stroke 28 (1997) 2119-2125
17. Barber P.A., Zhang J., Demchuk A.M., et al. Why are stroke patients excluded from TPA therapy?. Neurology 56 (2001) 1015-1020
18. Morgenstern L.B., Straub L., Chan W., et al. Improving delivery of acute stroke therapy: the TLL Temple Foundation Stroke Project. Stroke 33 (2002) 160-166
19. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke experience at eight centers and implications for community practice and patient care. Stroke 28 (1997) 1530-1540
20. Katzan I.L., Furlan A.J., Lloyd L.E., et al. Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland Area Experience. JAMA 283 (2000) 1151-1158
21. Grond M., Stenzel C., Schmulling S., et al. Early intravenous thrombolysis for acute ischemic stroke in community based approach. Stroke 29 (1998) 1544-1549
22. Grotta J.C., Burgin W.S., El-Mitwalli A., et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996-2000. Arch Neurol 58 (2001) 2009-2013
23. Marler J.R., Jones P.W., and Emr M. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke (1997), The National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, Md. http://www.ninds.nih.gov/health_and_medical/stroke_proceedings/titlepage .htm
24. Schmulling S., Grond M., Rudolf J., et al. One year follow up in acute stroke patients treated with rt-PA in clinical routine. Stroke 31 (2000) 1552-1554
25. Hill D., Woolfendeu A., Teal P.A., et al. Intravenous alteplase for stroke: the Canadian experience. Stroke Intervent 2 (2000) 3-8
26. Albers G.W., Bates V.E., Clark W., et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA 283 (2000) 1145-1150
27. The Work Group on Thrombolytic Therapy in Stroke. Position statement on the use of intravenous thrombolytic therapy in the treatment of stroke. www.aaem.org/positionstatements/thrombolytic-therapy.shtml
28. The CAEP Committee on Thrombolytic Therapy for Acute Ischemic Stroke. Position statement on thrombolytic therapy for acute ischemic stroke. CJEM 3 (2001) 8-14
29. del Zoppo G.J., Higashida R.T., Furlan A.J., et al. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 29 (1998) 4-11
30. Furlan A., Higashida R.T., Wechsler L., et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282 (1999) 2003-2011
31. Endo S., Kuwayama N., Hirashima Y., et al. Results of urgent thrombolysis in patients with major stroke and atherothrombotic occlusion of the cervical internal carotid artery. Am J Neuroradiol 19 (1998) 1169-1175
32. Kalafut M.A., and Saver J.L. The Acute Stroke Patient: The First Six Hours. In: Cohen S.N. (Ed). Management of Ischemic Stroke (2000), McGraw-Hill, New York 17-52
33. Lewandowski C.A., Frankel M., and Tomsick T.A. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke 30 (1999) 2598-2605
34. Broderick J for the IMS Study Investigators. The Interventional Management of Stroke (IMS) Study: Preliminary Results. Presented at the 7th International Symposium in Thrombolysis and Acute Stroke Therapy, May 27, 2002, Lyon, France.
35. Christou I., Alexandrov A.V., Burgin W.S., et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke 31 (2000) 1812-1816
36. Alexandrov A.V., and Grotta J.C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 59 (2002) 862-867
37. Qureshi A.I., Siddiqui A.M., Suri M.F., et al. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 51 (2002) 1319-1329
38. Song J.K., Cacayorin E.D., Campbell M.S., et al. Intracranial balloon angioplasty of acute terminal internal carotid artery occlusions. AJNR 23 (2002) 1308-1312